StreetInsider.com News Articles

Evommune Inc (EVMN) PT Lowered to $21 at RBC Capital

Wed, 09 Sep 2026 07:23:21 -0400

RBC Capital analyst Brian Abrahams lowered the price target on Evommune Inc (NYSE: EVMN) to $21.00 (from $29.00) while maintaining a Outperform rating.

Clear Street Reiterates Buy Rating on Evommune Inc (EVMN) Amid 15% Drop

Wed, 09 Sep 2026 06:58:24 -0400

Clear Street analyst Kaveri Pohlman reiterated a Buy rating and $28.00 price target on Evommune Inc (NYSE: EVMN).

The analyst comments "EVMN shares fell after P2b EVO756 in AD failed to meet primary or secondary endpoints at any dose through week-14. While disappointing given translational data supporting MRGPRX2 in AD, we believe the migraine program retains an independent shot on goal, reinforced by Lundbeck’s (Nasdaq Copenhagen: HLUN-B, NC) positive anti-PACAP ligand mAb data, providing strong readthrough to EVO756. P2b AD safety matched prior CSU experience: AST/ALT elevations occurred in a few patients (weeks 6–10) at the highest dose and were reversible.

Clear Street Reiterates Buy Rating on Evommune Inc (EVMN) Amid 15% Drop

Wed, 09 Sep 2026 06:58:24 -0400

Clear Street analyst Kaveri Pohlman reiterated a Buy rating and $28.00 price target on Evommune Inc (NYSE: EVMN).

Form 8-K Evommune, Inc. For: Sep 08

Wed, 09 Sep 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260909/27038550.html

Form 424B3 Evommune, Inc.

Wed, 09 Sep 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260909/27038567.html

Evommune's EVO756 fails atopic dermatitis trial endpoints

Tue, 08 Sep 2026 17:43:19 -0400

Evommune, Inc. (NYSE: EVMN) announced that its Phase 2b clinical trial of EVO756 in adults with moderate-to-severe atopic dermatitis did not meet its primary or secondary endpoints at any dose studied.

The randomized, double-blind, placebo-controlled trial enrolled 121 adults over a 12-week treatment period, with follow-up through Week 14. The primary endpoint was percent change in Eczema Area and Severity Index score from baseline at Week 12. The company said it does not plan to advance EVO756 in atopic dermatitis.

EVO756 was described as generally well tolerated, with a safety profile consistent with prior studies. Evommune said it plans to continue Phase

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis

Tue, 08 Sep 2026 17:43:00 -0400

- Trial did not meet the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at Week 12; EVO756 was generally well tolerated

- EVO301, the Company’s IL-18BP fusion protein, advances as lead atopic dermatitis program following positive Phase 2a proof-of-concept data

- Evommune to continue Phase 2b development of EVO756 in migraine prophylaxis

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)-- Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized,

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis

Tue, 08 Sep 2026 17:43:00 -0400

- Trial did not meet the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at Week 12; EVO756 was generally well tolerated

- EVO301, the Company’s IL-18BP fusion protein, advances as lead atopic dermatitis program following positive Phase 2a proof-of-concept data

- Evommune to continue Phase 2b development of EVO756 in migraine prophylaxis

Needham Starts Evommune Inc (EVMN) at Buy

Wed, 26 Aug 2026 06:20:24 -0400

Needham analyst Serge Belanger initiates coverage on Evommune Inc (NYSE: EVMN) with a Buy rating and a price target of $28.00.

For an analyst ratings summary and ratings history on Evommune Inc click here. For more ratings news on Evommune Inc click here.

Shares of Evommune Inc closed at $13.79 yesterday.

Form SCHEDULE 13G/A Evommune, Inc. Filed by: Andera Partners

Fri, 14 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260814/26931186.html

Form SCHEDULE 13G/A Evommune, Inc. Filed by: Andera Partners

Fri, 14 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260814/26931186.html

Form SCHEDULE 13G Evommune, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 14 Aug 2026 10:39:00 -0400

si-local-file:///var/storage/secattach/20260814/26926612.html

Form SCHEDULE 13G Evommune, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 14 Aug 2026 10:39:00 -0400

si-local-file:///var/storage/secattach/20260814/26926612.html

Evommune, Inc. (EVMN) Misses Q2 EPS by 20c

Fri, 07 Aug 2026 16:20:00 -0400

Evommune, Inc. (NYSE: EVMN) reported Q2 EPS of ($0.89), $0.20 worse than the analyst estimate of ($0.69).

For earnings history and earnings-related data on Evommune, Inc. (EVMN) click here.

Evommune Inc (EVMN) PT Lowered to $29 at RBC Capital

Fri, 07 Aug 2026 07:20:57 -0400

RBC Capital analyst Brian Abrahams lowered the price target on Evommune Inc (NYSE: EVMN) to $29.00 (from $30.00) while maintaining a Outperform rating.

Form 424B3 Evommune, Inc.

Thu, 06 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260806/26884025.html

Form 424B3 Evommune, Inc.

Thu, 06 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260806/26884025.html

Form 10-Q Evommune, Inc. For: Jun 30

Thu, 06 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260806/26883898.html

Form 10-Q Evommune, Inc. For: Jun 30

Thu, 06 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260806/26883898.html

Form 8-K Evommune, Inc. For: Aug 06

Thu, 06 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26883720.html

Form 8-K Evommune, Inc. For: Aug 06

Thu, 06 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26883720.html

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Thu, 06 Aug 2026 16:05:00 -0400

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026

‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027

‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference

‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)-- Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Thu, 06 Aug 2026 16:05:00 -0400

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026

‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027

‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference

‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Thu, 06 Aug 2026 16:05:00 -0400

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026

‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027

‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference

‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Thu, 06 Aug 2026 16:05:00 -0400

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026

‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027

‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference

‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline